Electrocardiographic Safety of Daily Hydroxychloroquine 400 mg Plus Azithromycin 250 mg as an Ambulatory Treatment for COVID-19 Patients in Cameroon

• 作者: Liliane Mfeukeu-Kuate William Djomo Ngatchou Mazou Ngou Temgoua Charles Kouanfack Daniel Lemoungoum Joel Noutakdie Tochie Armel Zemsi Lauriane Fomete Skinner Lekelem Sylvain Zemsi Joelle Sobngwi Thierry Ntandzi Christian Ngongang Ouankou Yves Wasnyo Antoinette Tsama Assiga Jan René Nkeck Ahmadou Musa Jingi Magellan Guewo Eric Walter Pefura Yone Charlotte Moussi Omgba Paul Owono Etoundi Jean Cyr Yombi Samuel Kingue Alain Menanga Jacqueline Ze Minkande Pierre Ongolo Zogo Jean Claude Mbanya Pierre Joseph Fouda Eugène Sobngwi
• 来源期刊: 心血管病(英文)
• 学科: 医学
• 关键词: Early Electrocardiographic Changes COVID-19 HYDROXYCHLOROQUINE AZITHROMYCIN Cameroon
• 年，卷（期）: 2021,（2）
• 页码范围: 106-112
• 页数: 7页
• 分类号: R54

摘要

<strong>Objective:</strong> <span style="font-family:Verdana;">To determine the early electrocardiographic changes in a cohort of ambulatory cameroonian COVID-19 patients treated with hydroxychlo</span><span style="font-family:Verdana;">- </span><span style="font-family:;" "=""><span style="font-family:Verdana;">roquine and Azithromycin. </span><b><span style="font-family:Verdana;">Design:</span></b><span style="font-family:Verdana;"> Prospective study. </span><b><span style="font-family:Verdana;">Setting:</span></b><span style="font-family:Verdana;"> Treatment centres of the city of Yaounde, Cameroon, from May 7</span>^{<span style="font-size:12px;font-family:Verdana;">th</span>}<span style="font-family:Verdana;"> to 24</span>^{<span style="font-size:12px;font-family:Verdana;">th</span>}<span style="font-family:Verdana;"> 2020. </span><b><span style="font-family:Verdana;">Participants:</span></b><span style="font-family:Verdana;"> We enrolled 51 consecutive confirmed COVID-19 on RT-PCR who having mild forms of COVID-19 and treated by hydroxychloroquine 200</span></span><span style="font-family:Verdana;"> </span><span style="font-family:;" "=""><span style="font-family:Verdana;">mg twice daily during seven #days plus Azithromycin 500 mg the first day and 250 mg the remaining 4 days as per national standard. </span><b><span style="font-family:Verdana;">Main Outcomes Measures:</span></b><span style="font-family:Verdana;"> The</span><b><span style="font-family:Verdana;"> </span></b><span style="font-family:Verdana;">primary end-point was the change in QTc interval between day 0 (D0), day 3 (D3) and day 7 (D7). Secondary endpoints were changes in all other cardiac electrical conductivity patterns and the occurrence of clinical arrhythmic events during the course of treatment. </span><b><span style="font-family:Verdana;">Results: </span></b><span style="font-family:Verdana;">The population (29 men and 22 women) was aged 39 ± 11 years (range 17 to 61 years). Mean Tisdale score was 3.35 ± 0.48. No sign